drugset / Trial / NCT05170451

Topical CBD for Musculoskeletal Pain

NCT05170451 ↗

Phase 2/3 Withdrawn University of Virginia
RandomizedCrossoverQuadruple-blindTreatment

Summary

Rationale: CBD is commonly being used as an over-the-counter treatment for musculoskeletal pain; however, no clinical trial has been performed to establish efficacy of CBD in humans for musculoskeletal pain. Hypothesis: CBD is more effective than placebo for relieving pain and improving patient-reported outcomes for musculoskeletal pain. Study Design: The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD or control and then crossover to the other condition for 2 additional weeks. Patients will apply the CBD or control cream to the affected area twice daily (approximately every 12 hours) for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.

Timeline

Start
2022-01
Primary completion
2022-06
Completion
2022-12

Outcome

Outcome not reported

Stopped: “Terminated due to hurdles of obtaining regulatory approval.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator CBD Unknown 50 mg/ml Topical